Sugi Predict

Sugi Predict / Compounds / SCHEMBL1008644

SCHEMBL1008644

SCHEMBL1008644

O=C(O)C(CC1CCCCC1)n1ncc(Oc2ccccc2)c(Cl)c1=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPY5R Q15761 1/20 0.39
▸ PREP P48147 1/20 0.39
▸ METAP2 P50579 1/20 0.38
▸ METAP1 P53582 1/20 0.38
▸ LMNA P02545 3/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ NPBWR1 P48145 3/20 0.36
▸ NR1H4 Q96RI1 1/20 0.35
▸ GPR132 Q9UNW8 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ EGLN1 Q9GZT9 1/20 0.35
▸ GRN P28799 1/20 0.34
▸ SORT1 Q99523 1/20 0.34
▸ MITF O75030 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008502 0.83 PREP (0.41) PREP
SCHEMBL1010867 0.82 FFAR4 (0.37) ALDH1A1MCHR1
SCHEMBL1008300 0.81 GCK (0.36) LMNASMN1; SMN2ALDH1A1HTTATM
SCHEMBL1008851 0.80 GRN (0.38) LMNASMN1; SMN2GRNSORT1MITF
SCHEMBL1009307 0.80 NPY5R (0.43) NPY5RMETAP2METAP1NR1H4GPR132
SCHEMBL4297479 0.79 GCK (0.41) NPY5R
SCHEMBL1008584 0.78 HIF1A (0.36) NPBWR1MEN1KMT2AALDH1A1
SCHEMBL1008862 0.77 NPY5R (0.41) NPY5RMETAP2METAP1NR1H4GPR132
SCHEMBL1008225 0.76 LMNA (0.36) LMNASMN1; SMN2NPBWR1MEN1KMT2A
SCHEMBL1008857 0.75 NPY5R (0.40) NPY5RMETAP2METAP1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
US-8258134-B2 Pyridazinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-09-04 — — US disclosed
EP-2268633-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-05 — — EP disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 — — US disclosed
WO-2009127544-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264434-A1 PYRIDAZINONE GLUCOKINASE ACTIVATORS GCK, GCKR, PDXK NPY5R 2254/4885PREP 1484/4885METAP2 1286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.